Archives
-
Cy5 amine (non-sulfonated) Labeling Guide
2026-09-22
Cy5 amine (non-sulfonated), SKU A8143, provides a primary amine for covalent attachment of a bright far-red fluorophore to proteins, peptides, polymers, and other compatible biomolecules. It is intended for controlled mixed-solvent research workflows, not direct use as an aqueous dye or for diagnostic and medical applications.
-
ASB3–MAVS Control of Antiviral Immunity
2026-09-21
The 2024 reference study identifies ASB3 as an E3 ligase that suppresses antiviral innate immunity by directing K48-linked ubiquitination and degradation of MAVS. Its reciprocal genetic, virological, and mechanistic evidence positions ASB3 as a regulatory checkpoint in RIG-I-like receptor signaling and provides a framework for fluorescence-based validation of related host–pathogen mechanisms.
-
Deracoxib–Doxorubicin Protection in Canine Cells
2026-09-21
The 2017 reference study tested whether Deracoxib could reduce doxorubicin-associated injury in cultured normal canine mammary epithelial cells. Its central finding was that Deracoxib lowered doxorubicin-related cytotoxicity and apoptosis while limiting nitrite accumulation, identifying nitric oxide modulation as a plausible component of the protective response.
-
Budesonide for Airway Inflammation Research
2026-09-20
Use Budesonide as a reproducible anti-inflammatory benchmark while pairing asthma inflammation models with biomimetic permeability measurements. This workflow helps distinguish biological efficacy from membrane partitioning and supports better decisions in respiratory disease research.
-
Making mRNA Delivery Visible: From Cargo to Translation
2026-09-19
A translational framework for using ARCA Cy5 EGFP mRNA (5-moUTP) to separate delivery, localization, endosomal escape, and protein expression when evaluating emerging mRNA carriers for ischemic disease.
-
ARCA Cy5 EGFP mRNA (5-moUTP) Workflow
2026-09-18
Build a direct, dual-readout workflow that separates mRNA uptake from protein expression in mammalian cells. ARCA capping, 5-methoxyuridine modification, Cy5 labeling, and EGFP translation make this reporter useful for benchmarking emerging delivery systems, including biodegradable polyester nanoparticles.
-
EZ Cap™ Cas9 mRNA (m1Ψ) Workflow Guide
2026-09-18
Build transient CRISPR-Cas9 experiments around a Cap1-capped, m1Ψ-modified Cas9 transcript designed for efficient translation and reduced innate immune stimulation. This practical guide connects product handling with mammalian-cell editing, time-course controls, nuclear-export studies, and troubleshooting for reproducible results.
-
Cl-Amidine: PAD4 Inhibition Evidence & Workflow
2026-09-17
Cl-Amidine trifluoroacetate salt is a research-grade PAD4 inhibitor with a reported in-vitro IC50 of 5.9 μM. Evidence connects PAD4 inhibition with reduced histone citrullination and altered NET biology, while murine septic-shock findings remain preclinical.
-
KDM3A–METTL16–PDK1 Axis in TKI Resistance
2026-09-17
The reference study identifies a coordinated epigenetic and post-transcriptional mechanism that elevates PDK1 and promotes EGFR-TKI resistance and tumor development. Its findings connect KDM3A-mediated histone demethylation with METTL16-dependent m6A stabilization of PDK1 mRNA, suggesting a mechanistic framework for biomarker development and combination treatment studies.
-
U3 snoRNA–DDX21 Control of Mitotic Progression
2026-09-16
The reference study shows that U3 snoRNA is an active regulator of mitosis rather than merely a passenger retained on chromosome surfaces. By combining cellular perturbation, localization analysis, and in vitro condensate reconstitution, the authors identify a reciprocal U3 snoRNA–DDX21 system that helps organize the perichromosomal region and supports mitotic progression.
-
Bazedoxifene and IL-6/GP130 Cancer Signaling
2026-09-16
Shi and colleagues identify bazedoxifene as a repurposing candidate that may inhibit the IL-6/GP130 signaling axis, linking an established osteoporosis medicine to a cancer-relevant survival pathway. Their review integrates pathway biology, computational drug-repositioning evidence, and preclinical oncology findings while highlighting the experiments needed to establish therapeutic selectivity and clinical relevance.
-
Abiraterone Acetate in Patient-Derived Spheroids
2026-09-15
Abiraterone acetate is a CYP17 inhibitor whose effects in patient-derived prostate spheroids require more than a viability readout. This guide connects steroidogenesis, exposure control, and orthogonal 3D assay endpoints to improve translational prostate cancer research.
-
ARCA Cy5 EGFP mRNA: Assay Guide
2026-09-15
ARCA Cy5 EGFP mRNA (5-moUTP) combines covalent Cy5 tracking with EGFP expression for direct analysis of mRNA delivery, localization, and translation in mammalian cells. This 5-methoxyuridine modified mRNA is supplied as a 996-nucleotide, ARCA-capped transcript for fluorescence microscopy, flow cytometry, and controlled transfection workflows.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflow
2026-09-14
EZ Cap Cy5 Firefly Luciferase mRNA supports a failure-aware workflow that separates cellular uptake from productive translation. Learn how to apply dual optical readouts to delivery optimization, intracellular trafficking, and translational assay design.
-
Recombinant Human FGF-19 in Renal Injury Research
2026-09-14
Recombinant Human FGF-19 offers a defined way to examine endocrine metabolic signaling alongside septic kidney-injury phenotypes. This article connects FGF-19 reagent selection with WIP1–p38 MAPK pyroptosis research while separating validated evidence from exploratory assay design.